Biolex's Locteron has promising Phase IIB results; Celgene exceeds earnings expectations;

 @FierceBiotech: Novartis doubles Boston expansion to $600M. Report | Follow @FierceBiotech

Slideshow: Notorious Names in Biopharma. Slideshow

Special Report: Top 10 Women in Biotech. Article

Special Report: Pharma's Biggest Flops. Report

> According to its released results, Biolex Therapeutics' Hepatitis C drug Locteron is better tolerated than its competitor PEG-Intron. The Phase IIB trial lasted 72 weeks, with Locteron administered half as often as PEG-Intron, but with the same or better efficacy. Biolex release

> Celgene posted higher than expected Q3 earnings ($910.1 million), including higher sales ($641.3 million) for its multiple myeloma drug Revlimid. Report

> Can brain signals can control prosthetic arms? Item

> Researchers have found a more effective polio vaccine--a double strain known as a bivalent vaccine--than the previously used monovalent and trivalent vaccines, reducing polio cases by up to 90 percent. Story

> Evotec and Zhejiang Jingxin have entered a licensing agreement for Zhejiang's insomnia treatment, EVT 201. The companies did not disclose the financial agreement, other than it is predominantly royalty based and includes a small upfront payment. Evotec release

> La Jolla, CA-based Regulus Therapeutics received a $10 million equity investment from Sanofi-aventis as part of its June alliance. The alliance is worth an estimated $750 million total for microRNA products. Regulus release

> Sanofi Pasteur this week reported the results of a Phase III clinical trial comparing its investigational Fluzone intradermal candidate with Fluzone administered by the traditional intramuscular method. Study results showed that the Fluzone intradermal has a lower antigen content and injection volume. Article

And Finally... There is a particular emphasis these days on developing drugs that reduce the chances for abuse, particularly for opioid-based prescriptions drugs. Along those lines, Highland Pharmaceuticals says it has "extraction resistant technology" that makes it difficult to abuse opioid-based medications. Highland says it can produce products such as oxycodone in solid dose, oral tablets that "cannot be crushed for inhalation or extracted for injection." Story

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.